TOPIC: Indian generics expected to get the green light

timesofindia.indiatimes.com/home/science...cleshow/49966218.cms

NEW DELHI: In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial new direct-acting antiviral drugs treating the disease.

The waiver for sofosbuvir and ledipasvir co-formulation and for daclatasvir is expected to bring the generic version of these drugs, which cost a fraction of the branded versions, into the Indian market within weeks. Some patients facing a threat to life currently import these drugs at a huge cost.

According to the World Health Organisation, about 12 million people are infected with Hepatitis C in India. India is now one of the few countries where generics are available for interferon-free treatment. Pegylated interferon is an old, expensive, injectable chemotherapy drug with serious side effects used to treat Hep C in combination with sofosbuvir and ribavirin.

But next door in Pakistan there is interference from interferon...

"in the process of preparing guidelines at the national level but since they still have over 0.3million vials of interferon, they have decided to wait until the stock ends."

tribune.com.pk/story/1000800/taking-on-b...-c-blocked-by-lobby/

Joy wrote:
Getting rid of the "Rat Poison" first.

Sounds like NHS England, although hopefully now, this will become less and less.

We have a very similar Hep C profile. It is encouraging to know of your success. All the best to you.